证券代码：688566 证券简称：吉贝尔 江苏吉贝尔药业股份有限公司 2025 年第二次临时股东大会 会议资料 二〇二五年九月 2025 年第二次临时股东大会会议须知 为了维护公司全体股东的合法权益，确保股东大会的正常秩序和议事效 率，保证大会的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证 券法》《上市公司股东会规则》以及《江苏吉贝尔药业股份有限公司章程》等相 关规定，江苏吉贝尔药业股份有限公司（以下简称"公司"）特制定本次股东大 会会议须知： 一、股东大会设会务组，由公司董事会秘书负责会议的程序安排和会务工 作； 二、为保证本次大会的严肃性和正常秩序，切实维护股东的合法权益，务 请出席大会的股东或其代理人及其他出席、列席人员准时到达会场签到确认参 会资格。会议开始后，会议登记应当终止，由会议主持人宣布现场出席会议的 股东和代理人人数及所持有的表决权数量； 三、会议按照会议通知上所列顺序审议、表决议案； 四、股东及股东代理人参加股东大会依法享有发言权、质询权、表决权等 权利。股东及股东代理人参加股东大会应认真履行其法定义务，不得侵犯公司 和其他股东及股东代理人的合法权益，不得扰乱股东大会的正常秩序 ...

Core Points - The article discusses the latest developments in a lawsuit involving Jibeier and Hubei Jiuzhoutong Pharmaceutical Co., Ltd. regarding a contract dispute over the promotion of the drug Nigulol tablets [1][2] - The lawsuit has undergone multiple legal proceedings, with Jiuzhoutong as the plaintiff and Jibeier as the defendant in the main case, while Jibeier has counterclaimed [1] - The amounts involved in the case include 99.08262 million yuan for the main case and 6 million yuan for the counterclaim, with 60 million yuan involved in the appeal and retrial stages [1] Legal Proceedings Summary - First Instance: The Wuhan Intermediate People's Court issued a civil judgment in 2021 [2] - Second Instance: Jiuzhoutong appealed the first-instance judgment, leading to a civil judgment by the Hubei High People's Court in 2022 [2] - Retrial: Jiuzhoutong's application for retrial was rejected by the Supreme People's Court in 2023 [2] - Supervision Application: Jiuzhoutong's request for supervisory review was not supported by the Hubei Provincial People's Procuratorate, indicating that the previous judgment did not meet the conditions for supervision [2] Financial Impact - As of the announcement date, the comprehensive results of the various stages of judgment and decisions suggest that the case is not expected to have a significant impact on Jibeier's financial status and operational results for the current and future periods [2]

证券代码：688566 证券简称：吉贝尔 公告编号：2025-042 江苏吉贝尔药业股份有限公司 关于诉讼事项进展的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 截至本公告披露日，湖北省武汉市中级人民法院就该案件作出《民事判决书》 〔（2021）鄂 01 民初 563 号〕，湖北省高级人民法院就该案件作出《民事判决书》 〔（2022）鄂民终 1033 号〕，中华人民共和国最高人民法院作出《民事裁定书》 〔（2023）最高法民申 2912 号〕，湖北省人民检察院作出《不支持监督申请决定 书》（鄂检民监〔2025〕53 号-4）。根据上述判决、裁定或决定结果，预计不会对 公司本期及期后财务状况及经营成果等产生重大影响。 1 案件所处的诉讼阶段：湖北九州通和医药有限公司（本诉原告、反诉被 告、二审阶段上诉人、再审阶段申请人，抗诉阶段申请人，简称"九州 通和"）不服法院判决，向湖北省人民检察院申请提起抗诉，湖北省人 民检察院不支持九州通和的监督申请。 公司所处的当事人地位：本诉被告，反诉原告，二审阶段被上诉人 ...

Core Viewpoint - Jiangsu Jibeier Pharmaceutical Co., Ltd. has announced a cash dividend distribution of 0.26 yuan per share (including tax) for the first half of 2025, totaling approximately 51.85 million yuan [2][5]. Summary by Sections Dividend Distribution Plan - The profit distribution plan was authorized by the shareholders' meeting on May 28, 2025, and approved by the board of directors on August 29, 2025 [2][3]. - The distribution amount does not exceed the net profit attributable to shareholders for the first half of 2025 [3]. Distribution Details - The total number of shares before the distribution is 199,430,865 [5]. - The cash dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the day before the dividend record date [4]. Implementation Method - The dividends will be distributed through the clearing system of the China Securities Depository and Clearing Corporation for shareholders who have completed designated transactions [7]. - Specific entities, such as Zhenjiang Zhongtian Investment Consulting Co., Ltd. and Nantong Huirui Investment Co., Ltd., will receive dividends directly from the company [8]. Taxation Information - For individual shareholders holding shares for over one year, the dividend income is exempt from personal income tax, resulting in an actual cash dividend of 0.26 yuan per share [9]. - For shares held for less than one year, the company will not withhold personal income tax at the time of distribution, but tax will be calculated and deducted upon the transfer of shares [10]. - For Qualified Foreign Institutional Investors (QFIIs), a 10% withholding tax will apply, resulting in a net cash dividend of 0.234 yuan per share [11].

江苏吉贝尔药业股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/9/16 | 2025/9/17 | 2025/9/17 | 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经江苏吉贝尔药业股份有限公司（以下简称"公司"）2025 年 5 月 28 日的2024年年度股东大会授权公司董事会制定实施，并经公司第四届董 事会第十七次会议审议通过，具体情况如下： 证券代码：688566 证券简称：吉贝尔 公告编号：2025-041 本次利润分配预案符合相关法律法规、规范性文件及《公司章程》等有关规 定，本次利润分配预案拟分配金额未超过公司 2025 年半年度归属于上市公司股东 的净利润。本次利润分配预案属于公司 2024 年年度股东大会授权董事会决策的权 限范围并在有效期内，经公司董事会审议通过后，无需提交公司股东大会审议。 二、 分配方案 1. 发放 ...

Group 1: Tangrenshen - The company sold 2.9452 million pigs from January to July 2025, with an expected annual output of 5-5.5 million pigs [1] - The "company + farmer" model accounted for 80.64% of the fat pig output, with the proportion of new Dan series breeding pigs increasing from 56% to 76% [1] - The production cost of piglets decreased by 41 yuan per head, while the fattening cost dropped to 12.71 yuan per kilogram as of June 2025 [1] - The company plans to increase investment in meat business in the second half of 2025, aiming to develop a high-end fresh meat brand and promote nationwide meat business [1] Group 2: Jibeier - The antidepressant JJH201501 has completed Phase III clinical enrollment, follow-up, and data analysis, with a summary report being drafted [2] - Phase II clinical trials showed significant efficacy and good safety for JJH201501, while JJH201601 has completed Phase I and is undergoing Phase IIa trials [2] - Sales revenue for Niquilol tablets reached 91.0388 million yuan in the first half of 2025, representing a year-on-year growth of 38.31% [2] - The company has established a deuterated technology platform to advance the development of multiple deuterated new drugs [2] - A cash dividend distribution plan has been set, proposing a payout of 2.60 yuan per 10 shares for the first half of 2025 [2] Group 3: Chengquan Capital - Chengquan Capital was established in July 2015 in Beijing with a registered capital of 500 million yuan [3] - The company was founded by Hu Jiguang, a prominent figure in the asset management industry with 28 years of experience in securities and futures investment [3] - The investment research team consists of members from leading securities firms and influential research institutions, known for their rich experience and strong risk control capabilities [3] - The company aims to achieve a win-win situation for clients, employees, and shareholders, aspiring to become a respected and influential investment institution in the domestic capital market [3]

Core Viewpoint - The company Gibber has reported a mid-year dividend distribution and significant growth in revenue and net profit, driven by its innovative pharmaceutical products [1] Financial Performance - Gibber achieved a revenue of 455 million yuan in the first half of the year, representing a year-on-year growth of 4.90% [1] - The net profit for the same period was 149 million yuan, showing a year-on-year increase of 22.38% [1] Product Development and Sales - The company’s first-class compound antihypertensive drug, Niqunlor Tablets, generated a revenue of 91.04 million yuan in the first half of the year, with a year-on-year growth of 38.31% [2] - Gibber's antidepressant drug JJH201501 is expected to submit its market application within the year, with a projected peak sales of 2 billion yuan [3] - The company has developed a deuterated technology platform, which has led to the creation of multiple new drugs, including JJH201701 for acid reduction and JJH201801 for gallbladder inflammation [4] Clinical Trials and Research - The anticancer drug JJH201601 is currently undergoing Phase IIa clinical trials, showing significant tumor suppression effects in various models [5] - The company’s liposome drug development platform is noted for its advanced production capabilities, including short production cycles and high encapsulation rates [5]

Core Viewpoint - The recent financial report of Jibeier (688566) shows a positive growth trend in revenue and net profit, indicating improved profitability and operational efficiency [1] Financial Performance - As of the end of the reporting period, the company's total revenue reached 455 million yuan, a year-on-year increase of 4.9% [1] - The net profit attributable to shareholders was 149 million yuan, up 22.38% year-on-year [1] - In Q2, total revenue was 253 million yuan, reflecting a 5.72% increase compared to the same quarter last year [1] - The net profit for Q2 was approximately 99.78 million yuan, showing a significant increase of 43.59% year-on-year [1] - The gross margin improved to 89.79%, with a year-on-year increase of 0.16%, while the net margin rose to 32.79%, up 16.69% year-on-year [1] Cost and Efficiency Metrics - Total selling, administrative, and financial expenses amounted to 256 million yuan, accounting for 56.32% of revenue, which is a 9.59% increase year-on-year [1] - Earnings per share (EPS) increased to 0.75 yuan, a rise of 15.38% year-on-year [1] - The operating cash flow per share was 0.79 yuan, reflecting a 17.88% increase year-on-year [1] Business Model and Market Position - The company's performance is primarily driven by marketing efforts, necessitating a thorough examination of the underlying factors [2] - The company has a strong market position in the leukocyte-promoting drug sector, particularly with its product Likujun, which is effective in treating leukopenia and thrombocytopenia [4][5] Technical Barriers and Intellectual Property - The synthesis, separation, and purification of the raw material for Likujun are complex, establishing high-quality control technical barriers [5] - The company has secured patents for the preparation methods and uses of Likujun's crystal forms, enhancing its market position and technical barriers until December 2041 [5] Investment Interest - Several funds have recently increased their holdings in Jibeier, indicating growing institutional interest [4]

Financial Performance - Company reported a revenue of 455 million yuan for the first half of the year, representing a year-on-year growth of 4.90% [1] - Net profit attributable to shareholders reached 149 million yuan, with a year-on-year increase of 22.38% [1] - Company announced a cash dividend of 2.60 yuan per 10 shares for 2024, totaling 51.85 million yuan, reflecting strong profitability and commitment to shareholders [1] Product Performance - The sales of the product "Niqinluo Tablets" grew significantly, achieving a revenue of 91.04 million yuan, a year-on-year increase of 38.31%, becoming a key driver for revenue growth [2] - The product is recognized as the first fixed-dose combination of calcium channel blockers and beta-blockers in China, enhancing patient compliance and expanding the applicable population [2][3] - Another core product, "Likujun Tablets," is expected to drive future revenue growth, especially in oncology, due to its dual effects of prevention and treatment [3] R&D Progress - Company has made significant advancements in new drug development, with a focus on innovative drug research and a growing R&D team, increasing from 107 to 130 personnel [4] - The antidepressant drug JJH201501 has shown promising results in clinical trials, demonstrating significant efficacy and safety, and has completed phase III clinical enrollment [4] - The anti-tumor drug JJH201601 is progressing well in clinical trials, showing superior efficacy compared to existing treatments and good safety profiles [5][6] Market Environment - The domestic innovative drug policy environment has been improving, providing favorable opportunities for the development of innovative pharmaceutical companies [6] - With a solid product foundation, efficient marketing system, and a rich pipeline of R&D projects, the company is well-positioned to strengthen its competitive advantage and achieve sustained growth [6]

Core Viewpoint - The company announced that it will hold the second extraordinary general meeting of shareholders in 2025 on September 26, 2025, to discuss the proposal to cancel the supervisory board and amend the company's articles of association and certain corporate governance systems [1] Group 1 - The extraordinary general meeting is scheduled for September 26, 2025 [1] - The agenda includes a proposal to cancel the supervisory board [1] - Amendments to the company's articles of association and certain corporate governance systems will also be discussed [1]